BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 34365012)

  • 1. Validation, Implementation, and Clinical Impact of the Oncomine Myeloid Targeted-Amplicon DNA and RNA Ion Semiconductor Sequencing Assay.
    Ferrone CK; Wong H; Semenuk L; Werunga B; Snetsinger B; Zhang X; Zhang G; Lui J; Richard-Carpentier G; Crocker S; Good D; Hay AE; Quest G; Carson N; Feilotter HE; Rauh MJ
    J Mol Diagn; 2021 Oct; 23(10):1292-1305. PubMed ID: 34365012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Utility of Implementing a Frontline NGS-Based DNA and RNA Fusion Panel Test for Patients with Suspected Myeloid Malignancies.
    Bhai P; Hsia CC; Schenkel LC; Hedley BD; Levy MA; Kerkhof J; Santos S; Stuart A; Lin H; Broadbent R; Nan S; Yang P; Xenocostas A; Chin-Yee I; Sadikovic B
    Mol Diagn Ther; 2022 May; 26(3):333-343. PubMed ID: 35381971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Validation of a Myeloid Next-Generation Sequencing Panel for Single-Nucleotide Variants, Insertions/Deletions, and Fusion Genes.
    Izevbaye I; Liang LY; Mather C; El-Hallani S; Maglantay R; Saini L
    J Mol Diagn; 2020 Feb; 22(2):208-219. PubMed ID: 31751678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Utility of Targeted Next-Generation Sequencing Assay to Detect Copy Number Variants Associated with Myelodysplastic Syndrome in Myeloid Malignancies.
    Jiang L; Pallavajjala A; Huang J; Haley L; Morsberger L; Stinnett V; Hardy M; Park R; Ament C; Finch A; Shane A; Parish R; Nozari A; Long P; Adams E; Smith K; Parimi V; Dougaparsad S; Long L; Gocke CD; Zou YS
    J Mol Diagn; 2021 Apr; 23(4):467-483. PubMed ID: 33577993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analytical validation and performance characteristics of a 48-gene next-generation sequencing panel for detecting potentially actionable genomic alterations in myeloid neoplasms.
    Rosenthal SH; Gerasimova A; Ma C; Li HR; Grupe A; Chong H; Acab A; Smolgovsky A; Owen R; Elzinga C; Chen R; Sugganth D; Freitas T; Graham J; Champion K; Bhattacharya A; Racke F; Lacbawan F
    PLoS One; 2021; 16(4):e0243683. PubMed ID: 33909614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analytical Validation of an Automated Semiconductor-Based Next-Generation Sequencing Assay for Detection of DNA and RNA Alterations in Myeloid Neoplasms.
    Zbieranski N; Insuasti-Beltran G
    J Mol Diagn; 2024 Jan; 26(1):29-36. PubMed ID: 37879438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic alterations in Thai adult patients with acute myeloid leukemia and myelodysplastic syndrome-excess blasts detected by next-generation sequencing technique.
    Owattanapanich W; Herzig J; Jahn N; Panina E; Ruchutrakool T; Kungwankiattichai S; Issaragrisil S; Döhner H; Döhner K
    Ann Hematol; 2021 Aug; 100(8):1983-1993. PubMed ID: 33839881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of the Oncomine
    Williams HL; Walsh K; Diamond A; Oniscu A; Deans ZC
    Virchows Arch; 2018 Oct; 473(4):489-503. PubMed ID: 30105577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integration of Technical, Bioinformatic, and Variant Assessment Approaches in the Validation of a Targeted Next-Generation Sequencing Panel for Myeloid Malignancies.
    Thomas M; Sukhai MA; Zhang T; Dolatshahi R; Harbi D; Garg S; Misyura M; Pugh T; Stockley TL; Kamel-Reid S
    Arch Pathol Lab Med; 2017 Jun; 141(6):759-775. PubMed ID: 28557600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid and Automated Semiconductor-Based Next-Generation Sequencing for Simultaneous Detection of Somatic DNA and RNA Aberrations in Myeloid Neoplasms.
    Sande CM; Wu R; Yang G; Sussman RT; Bigdeli A; Rushton C; Chitturi A; Patel J; Szankasi P; Morrissette JJD; Lim MS; Elenitoba-Johnson KSJ
    J Mol Diagn; 2023 Feb; 25(2):87-93. PubMed ID: 36503148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical validation of the Ion Torrent Oncomine Myeloid Assay GX v2 on the Genexus Integrated Sequencer as a stand-alone assay for single-nucleotide variants, insertions/deletions, and fusion genes: Challenges, performance, and perspectives.
    Krishnamurthy K; Chai J; Liu X; Wang Y; Naeem R; Goldstein DY
    Am J Clin Pathol; 2024 Jun; ():. PubMed ID: 38823030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analytical Validation of a 37-Gene Next-Generation Sequencing Panel for Myeloid Malignancies and Review of Initial Findings Incorporating Updated 2022 Diagnostic and Prognostic Guidelines.
    Leung B; Aung H; Nandini A; Abdulrasool G; Lau C; Seymour L
    J Mol Diagn; 2024 May; 26(5):399-412. PubMed ID: 38367765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular genetic biomarkers in myeloid malignancies.
    Matynia AP; Szankasi P; Shen W; Kelley TW
    Arch Pathol Lab Med; 2015 May; 139(5):594-601. PubMed ID: 25152312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring.
    Luthra R; Patel KP; Reddy NG; Haghshenas V; Routbort MJ; Harmon MA; Barkoh BA; Kanagal-Shamanna R; Ravandi F; Cortes JE; Kantarjian HM; Medeiros LJ; Singh RR
    Haematologica; 2014 Mar; 99(3):465-73. PubMed ID: 24142997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of genome-wide copy number variants in myeloid malignancies using next-generation sequencing.
    Shen W; Paxton CN; Szankasi P; Longhurst M; Schumacher JA; Frizzell KA; Sorrells SM; Clayton AL; Jattani RP; Patel JL; Toydemir R; Kelley TW; Xu X
    J Clin Pathol; 2018 Apr; 71(4):372-378. PubMed ID: 29197855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analytical and Potential Clinical Performance of Oncomine Myeloid Research Assay for Myeloid Neoplasms.
    Park J; Kim HS; Lee JM; Jung J; Kang D; Choi H; Lee GD; Son J; Park S; Cho BS; Kim HJ; Kim S; Lee JW; Chung NG; Cho B; Zhang H; Khazanov NA; Choi J; Jung JW; Kim Y; Kim M
    Mol Diagn Ther; 2020 Oct; 24(5):579-592. PubMed ID: 32676933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical performance and utility of a comprehensive next-generation sequencing DNA panel for the simultaneous analysis of variants, TMB and MSI for myeloid neoplasms.
    Sahajpal NS; Mondal AK; Ananth S; Njau A; Ahluwalia P; Jones K; Ahluwalia M; Okechukwu N; Savage NM; Kota V; Rojiani AM; Kolhe R
    PLoS One; 2020; 15(10):e0240976. PubMed ID: 33075099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of copy number alterations in acute myeloid leukemia and myelodysplastic syndromes.
    Jacoby MA; Walter MJ
    Expert Rev Mol Diagn; 2012 Apr; 12(3):253-64. PubMed ID: 22468816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The utility of next-generation sequencing in diagnosis and monitoring of acute myeloid leukemia and myelodysplastic syndromes.
    Duncavage EJ; Tandon B
    Int J Lab Hematol; 2015 May; 37 Suppl 1():115-21. PubMed ID: 25976969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive Validation of Diagnostic Next-Generation Sequencing Panels for Acute Myeloid Leukemia Patients.
    Wagner U; Wong C; Camenisch U; Zimmermann K; Rechsteiner M; Valtcheva N; Theocharides A; Widmer CC; Manz MG; Moch H; Wild PJ; Balabanov S
    J Mol Diagn; 2022 Aug; 24(8):935-954. PubMed ID: 35718092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.